Last reviewed · How we verify
TCA IR
At a glance
| Generic name | TCA IR |
|---|---|
| Also known as | Kenalog®-40 Injection, Kenacort-A 40, Triamcinolone Acetonide Crystalline Suspension (TAcs) |
| Sponsor | Pacira Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip (PHASE2)
- Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes (PHASE4)
- Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee (PHASE3)
- Study of FX006 in Patients With Osteoarthritis of the Knee (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee (PHASE2)
- Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip (PHASE2)
- Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee (PHASE2)
- Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCA IR CI brief — competitive landscape report
- TCA IR updates RSS · CI watch RSS
- Pacira Pharmaceuticals, Inc portfolio CI